In the most recent trading session, Novavax (NVAX) closed at $6.41, indicating no shift from the previous trading day.

The FDA is expected to unpause the only protein-based COVID-19 vaccine's transition from emergency approval to full approval.

Have you ever wondered about what became of COVID vaccine companies after the pandemic settled down? Find out in this article ...

Some 20 travel staff at the FDA, who made arrangements for the regulator’s inspectors, will be getting their jobs back, as ...

FRIDAY, May 2, 2025 (HealthDay News) — U.S. Health and Human Services Secretary Robert F. Kennedy Jr. plans to change how ...

The US Department of Health and Human Services said Thursday that it aims to accomplish within four years a scientific feat ...

Too easily overlooked are non-influenza, non-COVID viruses and bacteria that are burgeoning and spreading unchecked — both in ...

COVID-19 booster is here, and public health officials are urging seniors and immunocompromised people to get protected ahead ...

Streptococcus Group A affects close to 20% of U.S. children, according to Dr. Joshua Osowicki, senior research fellow at the ...

The market expects ANI Pharmaceuticals (ANIP) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus ...

Hartford-based Aetna plans to pull out of Affordable Care Act health-insurance exchanges nationwide next year, parent company CVS Health announced on Thursday. "We're disappointed by the continued ...

The U.S. Health and Human Services Department says it will require placebo testing of "all new vaccines," raising questions ...